CDK1 and cancer: Unlike prior studies that have broadly explored CDK1 in pan-cancer contexts [13,14,22], this study uniquely integrates transcriptomic profiling, machine learning prioritization, and molecular simulations to systematically establish CDK1 as a dual-targetable therapeutic hub specifically in epithelial ovarian cancer.